Pluri (NASDAQ:PLUR) Announces Quarterly Earnings Results

Pluri (NASDAQ:PLUR) posted its earnings results on Thursday. The company reported ($0.55) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.66) by $0.11, FiscalAI reports. The company had revenue of $0.17 million for the quarter, compared to the consensus estimate of $0.66 million.

Pluri Price Performance

Shares of NASDAQ:PLUR traded up $0.00 during trading on Thursday, hitting $3.51. The company’s stock had a trading volume of 9,236 shares, compared to its average volume of 8,427. The company has a 50-day moving average of $3.36 and a 200-day moving average of $3.42. Pluri has a 12 month low of $2.82 and a 12 month high of $5.96. The firm has a market cap of $37.82 million, a price-to-earnings ratio of -0.71 and a beta of 0.75.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded shares of Pluri from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 1st. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Pluri presently has a consensus rating of “Hold” and an average price target of $12.00.

Hedge Funds Weigh In On Pluri

A hedge fund recently bought a new stake in Pluri stock. Jane Street Group LLC acquired a new position in Pluri Inc. (NASDAQ:PLUR) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 10,928 shares of the company’s stock, valued at approximately $47,000. Jane Street Group LLC owned 0.14% of Pluri as of its most recent SEC filing. Institutional investors own 16.59% of the company’s stock.

About Pluri

Pluri (NASDAQ:PLUR) is a clinical-stage biotechnology company focused on the development and manufacturing of placental-derived cell therapy products. The company’s proprietary three-dimensional microcarrier expansion platform enables large-scale, off-the-shelf production of PLX (placental expanded) cells, which are being investigated for a range of acute and chronic conditions. Pluri’s approach seeks to combine the regenerative and immunomodulatory properties of stromal cells with a scalable manufacturing process that does not require patient-specific cell harvesting.

Pluri advances its pipeline through internally funded research programs and strategic collaborations with academic institutions and government agencies.